ALK and non-small cell lung carcinoma: In the case of non-squamous NSCLC EGFR and ALK testing are recommended by the NCCN guidelines to stratify patients for targeted therapy approaches, and hopefully represent the starting point for a wide range of targeted therapy options in future.